Eli Lilly expands vaccine pipeline with US$3.83B acquisition of three biotech firms

Eli Lilly just dropped US$3.83 billion to acquire Curevo, LimmaTech Biologics, and The Vaccine Company, signaling an aggressive, critical pivot into the vaccine market. This triple acquisition, Lilly's eighth, ninth, and tenth M&A deals of 2026, dramatically expands its therapeutic reach beyond its dominant, but increasingly competitive, GLP-1 franchises. This strategic shift comes as the pharmaceutical giant aims to de-risk its future revenue streams amidst an intensifying battle for market share in the lucrative obesity and diabetes drug space, notably against rival Novo Nordisk. The acquired firms bring diverse and cutting-edge platforms, including robust bacterial vaccine candidates from Curevo, innovative glycoconjugate technologies from LimmaTech, and a promising mRNA-based platform from The Vaccine Company, positioning Lilly to tackle a broader spectrum of infectious diseases. The integration challenge now lies in rapidly advancing these diverse vaccine candidates through clinical trials, a process that can be lengthy and costly. Investors will be watching for early signs of pipeline progression and how effectively Lilly leverages these new platforms to compete with established vaccine players, ultimately reshaping its long-term growth trajectory and solidifying its presence in global health solutions.